Everest Medicines' Licensing Partner Pfizer Announces U.S. FDA Approves Etrasimod for Adults with Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Oct. 16, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (...
Everest Medicines Announces Interim Results for First Half of 2023
SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2023, ...
Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
SHANGHAI, March 30, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) reported positive topline results from a second Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate (S1P) ...
Phoenix Venture Partners LLC Raises 3rd Fund, PVP III LP
SAN MATEO, Calif., Feb. 1, 2021 /PRNewswire/ -- Phoenix Venture Partners LLC (PVP) announced today that it officially closed its latest flagship venture capital fund, PVP III LP at EOY 2020. The Fund was oversubscribed and its limited partners (both returning and new) are composed of sophisticate...
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
- BAVENCIO maintenance treatment significantly extended median overall survival versus standard of care in the Phase III JAVELIN Bladder 100 study - First and only immunotherapy to demonstrate a significant overall survival benefit in the first-line setting in a Phase III trial - BAVENCIO firs...
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media DARMSTADT, Germany and NEW YORK, Dec. 11, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion rec...
PostEra enters a multi-year strategic partnership with Pfizer Inc. to advance machine learning for Drug Discovery
SAN FRANCISCO, Dec. 7, 2020 /PRNewswire/ -- PostEra, a biotechnology company specializing in machine learning solutions for preclinical drug discovery, today announced a strategic partnership with Pfizer Inc. (NYSE: PFE) with the goal of accelerating small molecule drug discovery by developing a ...
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
Not intended for US-, Canada- and UK-based media DARMSTADT, Germany, and NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print inThe New England Journal of...
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with Locally Advanced or Metastatic Urothelial Carcinoma
DARMSTADT, Germany and NEW YORK, July 1, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab) for the maintenance treatment of patients with...
Merck and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media - Breakthrough Therapy Designation and Submission based on positive Phase III JAVELIN Bladder 100 study results - Supplemental Biologics License Application being reviewed under FDA Real-Time Oncology Review (RTOR) pilot program - JAVELIN B...
Merck and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Not intended for US-, Canada- and UK-based media DARMSTADT, Germany and NEW YORK, March 13, 2020 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced an update from the Phase III JAVELIN Head and Neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus stand...
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Not intended for US-, Canada- and UK-based media - At the planned interim analysis, Phase III JAVELIN Bladder 100 study met the primary endpoint of prolonging overall survival (OS) as a first-line maintenance treatment versus standard of care - BAVENCIO is the first immunotherapy to signifi...
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050
HONG KONG, Nov. 28, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today announced the efficacy and tolerability results from the subgroup analysis of Asian patients enrolled in the ARCHER 1050, a randomized, multicenter, multinational, open-label Phase 3 study evaluating the efficacy of VIZIMPRO® ...
Pfizer Unveils Positive Results from Asian Subgroup Analysis of ARCHER 1050
SINGAPORE, Nov. 25, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) today announced the efficacy and tolerability results from the subgroup analysis of Asian patients enrolled in the ARCHER 1050, a randomized, multicenter, multinational, open-label Phase 3 study evaluating the efficacy of VIZIMPRO® ...
Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
Not intended for US, Canada and UK-based media DARMSTADT, Germany, and NEW YORK, Nov. 8, 2019 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction ch...
FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma
DARMSTADT, Germany and NEW YORK, May 15, 2019 /PRNewswire/ -- Not intended for US, Canada and UK-based media * BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line treatment of patients with advanced renal cell carcinoma (RCC) * Phase III study show...
ViiV Healthcare Announces Positive New Dolutegravir Data for the Treatment of People Living With HIV Co-Infected With Tuberculosis
LONDON, March 6, 2018 /PRNewswire/ -- INSPIRING study results contribute to the extensive body of evidence for dolutegravir, the leading integrase strand transfer inhibitor, in diverse and hard to treat patient populations ViiV Healthcare, the global specialist HIV company, majority owned by G...
Merck and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients With Pre-Treated Advanced Gastric Cancer
DARMSTADT, Germany and NEW YORK, Nov. 28, 2017 /PRNewswire/ -- Not intended for UK-based media * Pivotal Phase III Javelin trial investigating avelumab as third-line treatment for patients with unresectable, recurrent or metastatic gastric cancer did not meet its pre-specified primary endpoi...
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
DARMSTADT, Germany, and NEW YORK, Sept. 21, 2017 /PRNewswire/ -- Not intended for US, Canadian and UK-based media * First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK * Builds on Bavencio's previ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pfizer Inc. - PFE
NEW YORK, Aug. 11, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims
on behalf of investors of Pfizer Inc. ("Pfizer" or the "Company") (NYSE:
PFE). Such investors are advised to contactRobert S. Willoughby at
rswilloughby@pomlaw.com
